Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature

BACKGROUND: Anti-tumor necrosis factor agents were the first biologic therapy approved for the management of Crohn's disease (CD). Heart failure (HF) is a rare but potential adverse effect of these medications. The objective of this report is to describe a patient with CD who developed HF after...

Descripción completa

Detalles Bibliográficos
Autores principales: Grillo, Thais Gagno, Almeida, Luciana Rocha, Beraldo, Rodrigo Fedatto, Marcondes, Mariana Barros, Queiróz, Diego Aparecido Rios, da Silva, Daniel Luiz, Quera, Rodrigo, Baima, Julio Pinheiro, Saad-Hossne, Rogerio, Sassaki, Ligia Yukie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638044/
https://www.ncbi.nlm.nih.gov/pubmed/34904114
http://dx.doi.org/10.12998/wjcc.v9.i33.10382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638044/
https://www.ncbi.nlm.nih.gov/pubmed/34904114
http://dx.doi.org/10.12998/wjcc.v9.i33.10382

Ejemplares similares